Table 1. Change in forced vital capacity % predicted per week in the CAPACITY 004 and 006 study.

	Study 004		Study 006		Combined studies
	Pirfenidone 2403 mg·day−1	Placebo	Pirfenidone 2403 mg·day−1	Placebo	Pirfenidone 2403 mg·day−1	Placebo
Week 0	74.5	76.2	74.9	73.1
Week 12	-1.2	-2.7	-1.5	-1.1	−1.3	−1.9
Week 24	-1.4	-3.9	-1.7	-4.5	−1.5	−4.2
Week 36	-2.6	-7.2	-2.5	-4.9	−2.6	−6.1
Week 48	-4.4	-9.2	-5	-6.9	−4.7	−8.0
Week 60	-6.6	-10.7	-7.4	-8	−7.0	−9.4
Week 72	-8	-12.4	-9	-9.6	−8.5	−11.0

CAPACITY: Clinical Studies Assessing Pirfenidone in IPF: Research of Efficacy and Safety Outcomes. Data from [24].